NASDAQ:ZYNE - Zynerba Pharmaceuticals Stock Price, News, & Analysis

$13.34
-0.15 (-1.11 %)
(As of 06/24/2019 06:00 AM ET)
Today's Range
$13.0312
Now: $13.34
$13.90
50-Day Range
$10.65
MA: $12.90
$15.65
52-Week Range
$2.75
Now: $13.34
$16.47
Volume1.40 million shs
Average Volume2.10 million shs
Market Capitalization$281.21 million
P/E RatioN/A
Dividend YieldN/A
Beta5.11
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZYNE
CUSIPN/A
Phone484-581-7505

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90,000.00
Book Value$3.27 per share

Profitability

Net Income$-39,910,000.00

Miscellaneous

Employees25
Market Cap$281.21 million
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) released its earnings results on Wednesday, May, 8th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. View Zynerba Pharmaceuticals' Earnings History.

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Zynerba Pharmaceuticals.

What price target have analysts set for ZYNE?

5 brokers have issued 12-month target prices for Zynerba Pharmaceuticals' stock. Their forecasts range from $8.09 to $36.00. On average, they expect Zynerba Pharmaceuticals' stock price to reach $23.0180 in the next year. This suggests a possible upside of 72.5% from the stock's current price. View Analyst Price Targets for Zynerba Pharmaceuticals.

What is the consensus analysts' recommendation for Zynerba Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynerba Pharmaceuticals.

What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (6/8/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We continue to look for Zygel’s NDA filing in 1H’20 and approval in 2H’20 as we had anticipated this Fast Track designation." (5/6/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate ZYNE Overweight. We focus our valuation on FXS, where we are encouraged by the open-label, long-term data, with meaningful and durable improvements that we see having predictive value for the pbo-controlled pivotal CONNECT-FX trial. On epilepsy indications, we await further data after a disappointment in focal epilepsy. Section may be found on pages 4 – 5.We use a discounted NPV revenue calculation that yields ~$8 for ZYN002 in the U.S. FXS market and ~$3 in the EU." (3/7/2019)

Has Zynerba Pharmaceuticals been receiving favorable news coverage?

News articles about ZYNE stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zynerba Pharmaceuticals earned a news impact score of 1.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Zynerba Pharmaceuticals.

Are investors shorting Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totalling 3,935,700 shares, an increase of 13.8% from the April 15th total of 3,459,900 shares. Based on an average daily trading volume, of 2,380,000 shares, the days-to-cover ratio is presently 1.7 days. Approximately 21.7% of the company's shares are sold short. View Zynerba Pharmaceuticals' Current Options Chain.

Who are some of Zynerba Pharmaceuticals' key competitors?

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), Insys Therapeutics (INSY), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Micron Technology (MU) and Alibaba Group (BABA).

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the folowing people:
  • Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 61)
  • Ms. Terri B. Sebree, Pres (Age 61)
  • Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 55)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 50)
  • Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 62)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Campbell Capital Management Inc. (0.86%), Bernardo Wealth Planning LLC (0.12%), Spark Investment Management LLC (0.11%) and Virtu Financial LLC (0.11%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Institutional Ownership Trends for Zynerba Pharmaceuticals.

Which institutional investors are selling Zynerba Pharmaceuticals stock?

ZYNE stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC. View Insider Buying and Selling for Zynerba Pharmaceuticals.

Which institutional investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was bought by a variety of institutional investors in the last quarter, including Campbell Capital Management Inc., Virtu Financial LLC and Bernardo Wealth Planning LLC. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher, John P Butler, Michael Rapp and Terri B Sebree. View Insider Buying and Selling for Zynerba Pharmaceuticals.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $13.34.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $281.21 million and generates $90,000.00 in revenue each year. The company earns $-39,910,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Zynerba Pharmaceuticals employs 25 workers across the globe.View Additional Information About Zynerba Pharmaceuticals.

What is Zynerba Pharmaceuticals' official website?

The official website for Zynerba Pharmaceuticals is http://www.zynerba.com/.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]


MarketBeat Community Rating for Zynerba Pharmaceuticals (NASDAQ ZYNE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  473 (Vote Outperform)
Underperform Votes:  376 (Vote Underperform)
Total Votes:  849
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel